Listing analysis and research matching Pfizer:
Biopharmaceutical partnering in China
Multinational pharmaceutical companies are increasingly investing in China through alliances and the building of new centres. Much of the investment is to supplement rather than replace the research and development already occurring outside China and is focused on development and processes than be easily codified and regulated.
Bristol Myers-Squibb expands partnerships
In April 2007 Bristol-Myers Squibb Co entered two collaborations with Pfizer Inc in the field of anticoagulants and metabolic diseases worth up to US$1 billion. The deal comes close on the heals of another deal with AstraZeneca in January 2007 worth up to US$1 billion. Such deals are part of an interesting partnering strategy currently being pursued by Bristol Myers-Squibb to reduce the costs of marketing and sales and concentrate its efforts on discovery and early development. The fact that companies like Pfizer and AstraZeneca are beginning to invest such huge sums of money in the discovery and early development efforts of companies like Bristol Myers-Squibb shows how desperate the competition is for big pharmaceutical companies to fill their product pipelines.
Pfizer streamlines research to prepare for post-Lipitor world
Pfizer is going through major structural changes designed to streamline the organisation and position itself for the post Lipitor era. In January 2007 Pfizer announced that it would axe 10% of its global workforce by the end of 2008 to streamline its operations and achieve $2 billion in cost savings. The cuts were expected to lead to the closure of two manufacturing plants (Brooklyn and Omaha) and five research centers in the United States, plants in Japan (Nagoya) and France (Amboise) and the selling of a factory in Germany (Feucht).
Big hopes from small technologies
Promising smaller, lighter, quicker and better-performing materials, components and systems, nanotechnology could open new opportunities for collaborations in a number of sectors ranging from pharmaceuticals to medical devices, chemicals, energy and technology. That's what the proponents of the technology argue, anyway.
Exubera shows the importance of having an exit strategy
Pfizer has announced that it would drop Exubera, its poorly selling inhaled insulin developed in partnership with Nektar Therapeutics. Unfortunately a tough business orientated decision was turned into something akin to an alliance manager's worst nightmare. It seems that something went badly wrong in the communication between the partners with Nektar Therapeutics claiming that it only learned about the decision from Pfizer's press release.
Pfizer invests in web-based software company
Why is Pfizer so heavily behind a struggling web-based software company operating in a crowded space?
